These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11517410)

  • 1. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Clark KW; Smith PS; Joseph JT; Mazullo JM; De Girolami U; Letvin NL; Koralnik IJ
    J Neurovirol; 2001 Aug; 7(4):318-22. PubMed ID: 11517410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
    Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy.
    Koralnik IJ; Du Pasquier RA; Letvin NL
    J Virol; 2001 Apr; 75(7):3483-7. PubMed ID: 11238876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of survival in progressive multifocal leukoencephalopathy.
    Marzocchetti A; Tompkins T; Clifford DB; Gandhi RT; Kesari S; Berger JR; Simpson DM; Prosperi M; De Luca A; Koralnik IJ
    Neurology; 2009 Nov; 73(19):1551-8. PubMed ID: 19901246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope.
    Koralnik IJ; Du Pasquier RA; Kuroda MJ; Schmitz JE; Dang X; Zheng Y; Lifton M; Letvin NL
    J Immunol; 2002 Jan; 168(1):499-504. PubMed ID: 11751998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Kuroda MJ; Schmitz JE; Zheng Y; Martin K; Peyerl FW; Lifton M; Gorgone D; Autissier P; Letvin NL; Koralnik IJ
    J Virol; 2003 Nov; 77(22):11918-26. PubMed ID: 14581528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy.
    Koralnik IJ
    J Neurovirol; 2002 Dec; 8 Suppl 2():59-65. PubMed ID: 12491153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies.
    Du Pasquier RA; Autissier P; Zheng Y; Jean-Jacques J; Koralnik IJ
    AIDS; 2005 Dec; 19(18):2069-76. PubMed ID: 16284455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy.
    Lima MA; Marzocchetti A; Autissier P; Tompkins T; Chen Y; Gordon J; Clifford DB; Gandhi RT; Venna N; Berger JR; Koralnik IJ
    J Virol; 2007 Apr; 81(7):3361-8. PubMed ID: 17229701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy.
    Lima MA; Bernal-Cano F; Clifford DB; Gandhi RT; Koralnik IJ
    J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1288-91. PubMed ID: 20710013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors.
    Tan CS; Ghofrani J; Geiger E; Koralnik IJ; Jost S
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):220-224. PubMed ID: 31513076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human polyomavirus JC latency and reactivation status in blood of HIV-1-positive immunocompromised patients with and without progressive multifocal leukoencephalopathy.
    Andréoletti L; Dubois V; Lescieux A; Dewilde A; Bocket L; Fleury HJ; Wattré P
    AIDS; 1999 Aug; 13(12):1469-75. PubMed ID: 10465069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
    PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy.
    Gasnault J; Kahraman M; de Goër de Herve MG; Durali D; Delfraissy JF; Taoufik Y
    AIDS; 2003 Jul; 17(10):1443-9. PubMed ID: 12824781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.
    Khanna N; Wolbers M; Mueller NJ; Garzoni C; Du Pasquier RA; Fux CA; Vernazza P; Bernasconi E; Viscidi R; Battegay M; Hirsch HH;
    J Virol; 2009 May; 83(9):4404-11. PubMed ID: 19211737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy.
    Marzocchetti A; Lima M; Tompkins T; Kavanagh DG; Gandhi RT; O'Neill DW; Bhardwaj N; Koralnik IJ
    Virology; 2009 Jan; 383(2):173-7. PubMed ID: 19062062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy.
    Andréoletti L; Lescieux A; Lambert V; Si-Mohamed A; Matta M; Wattré P; Bélec L
    J Med Virol; 2002 Jan; 66(1):1-7. PubMed ID: 11748651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and humoral immune response in progressive multifocal leukoencephalopathy.
    Weber F; Goldmann C; Krämer M; Kaup FJ; Pickhardt M; Young P; Petry H; Weber T; Lüke W
    Ann Neurol; 2001 May; 49(5):636-42. PubMed ID: 11357954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of JC virus genotype distribution and transcriptional control region rearrangements in human immunodeficiency virus-positive progressive multifocal leukoencephalopathy patients with and without highly active antiretroviral treatment.
    Ferrante P; Delbue S; Pagani E; Mancuso R; Marzocchetti A; Borghi E; Maserati R; Bestetti A; Cinque P
    J Neurovirol; 2003; 9 Suppl 1():42-6. PubMed ID: 12709871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient.
    Balduzzi A; Lucchini G; Hirsch HH; Basso S; Cioni M; Rovelli A; Zincone A; Grimaldi M; Corti P; Bonanomi S; Biondi A; Locatelli F; Biagi E; Comoli P
    Bone Marrow Transplant; 2011 Jul; 46(7):987-92. PubMed ID: 20921942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.